Zacks Investment Research on MSN

IONS Q1 earnings & sales beat, stock rises on raised '26 view

Ionis Pharmaceuticals IONS reported first-quarter 2026 adjusted loss per share of 30 cents, narrower than the Zacks Consensus ...

Ionis outlines 2026 revenue of $875M-$900M while lifting olezarsen peak sales view to >$3B

Q1 2026 earnings call highlights: raised olezarsen peak sales to $3B+, updated guidance, and key PDUFA dates—read the takeaways now.

Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicin…

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced the U.S. Food and Drug Administration (FDA) has ...

Ionis Pharmaceuticals Q1 Earnings Call Highlights

Ionis Pharmaceuticals (NASDAQ:IONS) reported sharply higher first-quarter 2026 revenue and raised its full-year outlook, ...
Zacks Investment Research on MSN

Compared to estimates, Ionis Pharmaceuticals (IONS) Q1 earnings: A look at key metrics

Ionis Pharmaceuticals (IONS) reported $246 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 86.4%. EPS of -$0.30 for the same period compares to -$0.75 a ...

Ionis Pharmaceuticals: Q1 Earnings Snapshot

Ionis Pharmaceuticals Inc. (IONS) on Wednesday reported a loss of $93 million in its first quarter. On a per-share basis, the Carlsbad, California-based company said it had a loss of 56 cents. Losses, ...
AOL

Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
Benzinga.com

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal

On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and ...
Benzinga.com

Drugmaker Ionis Pharmaceuticals Garners Analyst Praise For 'Pipeline Depth'

HC Wainwright initiated coverage on Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a commercial-stage biotech company focused on RNA-targeted therapeutics. Analyst Mitchell Kapoor says Ionis has used its ...
BioSpace

Ionis’ antisense drug stabilizes ultra-rare disease ahead of FDA decision

The pivotal study of zilganersen in Alexander disease missed a secondary endpoint, but analysts expect the FDA to approve the ...
Nasdaq

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ION582 ...
The Barre-Montpelier Times Argus

Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...